Weekly or Every Other Week: Reading a New-Onset Subgroup Against a Truck Driver's Two Colds
A single patient, in remission on weekly tocilizumab for new-onset GCA. The question isn't whether he needs the drug — it's whether a subgroup finding buried inside the trial that approved it actually applies to him.
Warren K., 68, drove long-haul freight for thirty-one years before his knees made the job's overnight stops impossible, and now spends most days restoring an old pickup truck in his garage — a project he was mid-fender-replacement on when the headache and scalp tenderness of new-onset GCA sent him to the emergency department two months ago. Biopsy confirmed it; he started tocilizumab weekly, subcutaneous, alongside the standard 26-week prednisone taper, and by every measure the disease has answered: his ESR and CRP normalized within a month, his prednisone is down to 5mg, and he hasn't had a flare. What's brought the team back to the regimen itself is smaller and more ordinary — two colds in eight weeks, both mild, both handled without antibiotics or a hospital visit, but two more than he'd normally get in a season, and enough to make everyone in the room wonder whether weekly IL-6 blockade is doing more immunosuppressive work than his disease currently needs.
The GiACTA trial that built tocilizumab's evidence base tested weekly and every-other-week dosing against each other, not only against placebo, and its 52-week subgroup data are what put Warren's question on the table: among new-onset patients, sustained remission ran 60% on weekly against 58% every other week, a gap small enough to read as no gap at all, while relapsing patients separated more clearly. He was new-onset from day one, so on that reading the schedule he is on is buying him nothing he couldn't have for half the injections. But that subgroup was descriptive rather than powered, and Stone and colleagues went back to the same trial's 3-year extension in 2022 for a stated reason: clinicians had begun acting on the 52-week slice. Followed out, it did not hold. Among the new-onset patients, 49% assigned to weekly were still flare-free at three years against 27% on every other week; median time to first flare was 577 days against 479; median cumulative glucocorticoid exposure was 3068mg against 4080mg, and the every-other-week arm's steroid saving was no longer statistically distinguishable from placebo at all. His two colds are real. What they are being weighed against is a schedule whose advantage only becomes visible past the window his own regimen has so far been judged in.
Stepping down, or staying the course
The 52-week subgroup split is the whole reason this is worth asking. GiACTA's new-onset patients reached sustained remission at 60% on weekly and 58% every other week — that is not a margin I would hold a man to twice the injection burden for. And two upper respiratory infections in eight weeks, in someone who tells us he doesn't usually get them, is at least a soft signal that the immunosuppressive load is running above what his disease currently needs. He was never a relapsing patient. On that endpoint, the population where weekly clearly separates isn't his.
That was the field's reading until 2022, and it is precisely the reading Stone and colleagues went back to GiACTA's three-year extension to test — they say so in the paper, because clinicians had started reserving weekly dosing for relapsing patients on the strength of that 52-week slice. Followed out, it didn't hold. Among new-onset patients, 49% stayed flare-free on weekly against 27% every other week, and median time to first flare was 577 days against 479. The 52-week endpoint wasn't wrong; it was too early to see where the two schedules separate.
I'd also be careful what the colds are doing to this conversation. Two mild upper respiratory infections in a 68-year-old with a white count of 5.8 and no neutropenia is close to background, and it's thin ground for a change that the same trial's longer data now price at roughly a gram of additional prednisone over three years — 4080mg against 3068mg — with the every-other-week arm's steroid saving not statistically separable from placebo at all. That's the trade you'd be making for his two colds. I'd keep him weekly.
Agreed: continue tocilizumab weekly, unchanged, and let the prednisone taper run as planned — the dosing question resolved once the three-year data were on the table rather than the 52-week subgroup alone.
Not agreed: what, if anything, the two infections warrant on their own. The clinical pharmacologist wants a repeat count in a month and an explicit trigger — a third infection, or any neutropenia — to reopen the dosing question rather than treat it as closed. The rheumatologist regards two mild upper respiratory infections in a winter as background, and would rather not build a monitoring rule around a signal he doesn't think is there.